1. Home
  2. TAK
  3. TAK News

Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) (TAK) News on August 11, 2025

Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth
TAK

GlobeNewswire

4 hours ago

Multiple Myeloma Global and Regional Market Analysis and Forecast Report 2025-2035 | Johnson & Johnson, Sanofi, AbbVie, Bristol-Myers Squibb, Takeda, Pfizer Drive Innovation and Growth

TAK

Newsfile

3 days ago

Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis

United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda
TAK

GlobeNewswire

4 days ago

United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda

Novavax banks on vaccine supply partnerships to boost 2025 revenue
TAK

Reuters

5 days ago

Novavax banks on vaccine supply partnerships to boost 2025 revenue

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights
TAK

PR Newswire

5 days ago

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar
TAK

Pharmaceutical Technology

5 days ago

Fresenius Kabi signs global licensing deal for Polpharma’s vedolizumab biosimilar

Blackstone Plans to Take Japan’s TechnoPro Private
TAK

The Wall Street Journal

5 days ago

Blackstone Plans to Take Japan’s TechnoPro Private

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight
TAK

PR Newswire

6 days ago

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM
TAK

GlobeNewswire

6 days ago

Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM

Xoma strikes deals to buy struggling biotechs HilleVax, Lava
TAK

BioPharma Dive

7 days ago

Xoma strikes deals to buy struggling biotechs HilleVax, Lava

Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas
TAK

GlobeNewswire

11 days ago

Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas

Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON
TAK

GlobeNewswire

11 days ago

Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
TAK

Benzinga

12 days ago

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

TAK

MT Newswires

12 days ago

Takeda Pharmaceutical Fiscal Q1 Core Earnings, Revenue Fall; Reiterates Fiscal 2025 Guidance

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
TAK

Business Wire

12 days ago

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
TAK

Zacks

a month ago

Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?

Will Strong Asceniv Sales Drive ADMA Biologics Further?
TAK

Zacks

a month ago

Will Strong Asceniv Sales Drive ADMA Biologics Further?

Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
TAK

PR Newswire

2 months ago

Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
TAK

Zacks

2 months ago

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
TAK

Zacks

2 months ago

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

Takeda Announces New Assignments of Directors
TAK

Business Wire

2 months ago

Takeda Announces New Assignments of Directors

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
TAK

Insider Monkey

2 months ago

Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
TAK

Zacks

2 months ago

ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?

EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
TAK

Pharmaceutical Technology

2 months ago

EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma

TAK

MT Newswires

2 months ago

Takeda Pharmaceutical Receives European Commission Approval for Adcetris Regimen to Treat Hodgkin Lymphoma

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
TAK

Business Wire

2 months ago

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

TAK

MT Newswires

2 months ago

Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint

TAK

Business Wire

2 months ago

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

TAK

MT Newswires

2 months ago

Xoma Royalty Acquires Mezagitamab Royalty, Milestone Rights From BioInvent

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
TAK

Business Wire

2 months ago

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

Takeda Taps Salesforce (CRM) for AI-Driven Customer Experience Platform
TAK

Insider Monkey

3 months ago

Takeda Taps Salesforce (CRM) for AI-Driven Customer Experience Platform

TAK

MT Newswires

3 months ago

Salesforce's Life Sciences Cloud Platform Chosen by Takeda

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
TAK

Business Wire

3 months ago

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices
TAK

Bloomberg

3 months ago

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

Top 4 GARP Stocks With Attractive PEG Ratios to Watch
TAK

Zacks

3 months ago

Top 4 GARP Stocks With Attractive PEG Ratios to Watch

TAK

MT Newswires

3 months ago

Sector Update: Health Care Stocks Decline Pre-Bell Thursday

TAK

MT Newswires

3 months ago

Sector Update: Health Care

TAK

MT Newswires

3 months ago

Takeda Pharmaceutical Fiscal Q4 Core Earnings Fall, Revenue Rises

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress
TAK

Business Wire

3 months ago

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know
TAK

Zacks

3 months ago

Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here's What You Should Know

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
TAK

Zacks

3 months ago

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 Earnings
TAK

GuruFocus.com

3 months ago

What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q4 2024 Earnings

TAK

MT Newswires

3 months ago

Novavax Updates Financial Terms With Takeda for Covid-19 Vaccine Agreement in Japan

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
TAK

Business Wire

3 months ago

BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers

TAK or DSNKY: Which Is the Better Value Stock Right Now?
TAK

Zacks

3 months ago

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice
TAK

Zacks

3 months ago

Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice

Best Value Stocks to Buy for April 30th
TAK

Zacks

3 months ago

Best Value Stocks to Buy for April 30th

Best Income Stocks to Buy for April 30th
TAK

Zacks

3 months ago

Best Income Stocks to Buy for April 30th

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
TAK

Business Wire

3 months ago

Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education

New Strong Buy Stocks for April 30th
TAK

Zacks

3 months ago

New Strong Buy Stocks for April 30th

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
TAK

Zacks

4 months ago

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK

Zacks

4 months ago

TAK vs. DSNKY: Which Stock Is the Better Value Option?

NMPA approves BBM and Takeda China’s haemophilia B therapy
TAK

Pharmaceutical Technology

4 months ago

NMPA approves BBM and Takeda China’s haemophilia B therapy

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
TAK

The Wall Street Journal

4 months ago

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?
TAK

Zacks

4 months ago

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
TAK

Zacks

4 months ago

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

Takeda Canada says Health Canada expands marketing authorization for HyQvia
TAK

TipRanks

4 months ago

Takeda Canada says Health Canada expands marketing authorization for HyQvia

TAK

MT Newswires

4 months ago

Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)
TAK

CNW Group

4 months ago

Takeda's HyQvia® receives expanded market authorization as maintenance therapy for chronic inflammatory demyelinating polyneuropathy (CIDP)

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
TAK

Zacks

5 months ago

Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

TAK or DSNKY: Which Is the Better Value Stock Right Now?
TAK

Zacks

5 months ago

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Takeda’s $770M deal deepens Big Pharma’s omics push
TAK

Pharma Voice

5 months ago

Takeda’s $770M deal deepens Big Pharma’s omics push

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
TAK

Benzinga

5 months ago

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda and Protagonist report topline outcomes from trial of rusfertide
TAK

Clinical Trials Arena

5 months ago

Takeda and Protagonist report topline outcomes from trial of rusfertide

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
TAK

Zacks

5 months ago

Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

TAK

MT Newswires

5 months ago

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
TAK

Business Wire

5 months ago

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist says Takeda-partnered drug succeeds in rare blood cancer
TAK

BioPharma Dive

5 months ago

Protagonist says Takeda-partnered drug succeeds in rare blood cancer

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?
TAK

Insider Monkey

5 months ago

Is Takeda Pharmaceutical Company Limited (TAK) the Best Low Price Pharma Stock to Invest In Right Now?

Takeda broadens its deal with BridGene for up to $770m
TAK

Pharmaceutical Technology

6 months ago

Takeda broadens its deal with BridGene for up to $770m

EMA approves Takeda’s Takhzyro pre-filled pen option for HAE
TAK

Pharmaceutical Technology

6 months ago

EMA approves Takeda’s Takhzyro pre-filled pen option for HAE

TAK

MT Newswires

6 months ago

Takeda Secures EMA Approval for Additional Injection Option for Hereditary Angioedema Drug

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAK

PR Newswire

6 months ago

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK

Zacks

6 months ago

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
TAK

Insider Monkey

6 months ago

Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
TAK

Zacks

6 months ago

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

BBI announces $31m facility for Shire to enhance asset finance
TAK

Leasing Life

6 months ago

BBI announces $31m facility for Shire to enhance asset finance

Are orexins the next golden child of neuroscience?
TAK

Pharma Voice

6 months ago

Are orexins the next golden child of neuroscience?

Takeda announces appointment of Julie Kim as CEO
TAK

Pharmaceutical Technology

6 months ago

Takeda announces appointment of Julie Kim as CEO

Christophe Weber, veteran Takeda CEO, to retire next year
TAK

BioPharma Dive

6 months ago

Christophe Weber, veteran Takeda CEO, to retire next year

TAK

MT Newswires

6 months ago

Takeda Pharmaceutical Names Julie Kim Chief Executive

TAK

MT Newswires

6 months ago

Takeda Pharmaceutical Fiscal Q3 Core Earnings Decline, Revenue Rises

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
TAK

Business Wire

6 months ago

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth
TAK

Business Wire

6 months ago

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

TAK

MT Newswires

6 months ago

Takeda Pharmaceutical Says Hema-Quebec to Cover HyQvia for Immunodeficiency Treatment

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age
TAK

CNW Group

6 months ago

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
TAK

Benzinga

6 months ago

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

TAK

MT Newswires

6 months ago

Neurocrine Amends Collaboration with Takeda on Osavampator

TAK

MT Newswires

7 months ago

Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year
TAK

CNW Group

7 months ago

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
TAK

GlobeNewswire

7 months ago

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Health Canada gives Takeda’s mCRC capsules market authorisation
TAK

Pharmaceutical Technology

7 months ago

Health Canada gives Takeda’s mCRC capsules market authorisation

TAK

MT Newswires

7 months ago

Takeda Canada Says Health Canada Granted Market Authorization for Fruzaqla

Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)
TAK

CNW Group

7 months ago

Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)

Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.
TAK

Barrons.com

7 months ago

Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.

TAK

MT Newswires

7 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
TAK

Benzinga

7 months ago

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency

TAK

MT Newswires

7 months ago

Takeda Pharmaceutical's Hyqvia Approved in Japan for Patients With Immune Disorders

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
TAK

Business Wire

7 months ago

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative
TAK

CNW Group

8 months ago

Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative

Share on Social Networks: